evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,908 questions · 3,101 findings · 509 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 571 · 18.4%GRADE not reported 358 · 11.5%Very low 723 · 23.3%Low 854 · 27.5%Moderate 489 · 15.8%High 106 · 3.4%

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Cardiac events (fatal) · patients receiving PD

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (fatal) compared with conventional therapy (moderate certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Cardiac events (non fatal) · patients receiving PD

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (non fatal) compared with conventional therapy (moderate certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Peritonitis · patients receiving PD

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (moderate certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Adverse events (episodes of peritonitis) ‐ treated with an aminoglycoside · patients receiving PD

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ treated with an… compared with conventional therapy (moderate certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Adverse events (episodes of peritonitis) ‐ not treated with an aminoglycoside · patients receiving PD

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ not treated with an… compared with conventional therapy (moderate certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in cardiovascular mortality (RR) Median compared with usual care (moderate certainty).

1 finding from 1 review

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

Time to first hospitalisation for heart failure during · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in heart failure hospitalisation, first (RR) Range of compared with usual care (moderate certainty).

1 finding from 1 review